Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 3,872,013 shares, a growth of 344.3% from the February 15th total of 871,389 shares. Based on an average daily volume of 692,194 shares, the days-to-cover ratio is currently 5.6 days.

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) opened at $7.29 on Monday. The company has a current ratio of 1.53, a quick ratio of 1.47 and a debt-to-equity ratio of 0.01. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share has a 1 year low of $6.92 and a 1 year high of $11.93. The stock has a market capitalization of $292.21, a P/E ratio of 3.78 and a beta of 1.50.

How to Become a New Pot Stock Millionaire

Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share (NASDAQ:AVDL) last posted its quarterly earnings results on Thursday, March 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.05). Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share had a return on equity of 15.80% and a net margin of 38.64%. The company had revenue of $34.20 million for the quarter, compared to the consensus estimate of $34.16 million. The business’s revenue for the quarter was down 20.6% on a year-over-year basis. analysts predict that Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share will post -1.15 earnings per share for the current year.

Several equities analysts have recently commented on AVDL shares. BidaskClub upgraded Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “sell” rating to a “hold” rating in a research report on Friday, March 2nd. ValuEngine lowered Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “hold” rating to a “sell” rating in a research report on Friday. Ladenburg Thalmann Financial Services reduced their price objective on Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share to $24.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Zacks Investment Research upgraded Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share presently has an average rating of “Hold” and a consensus price target of $20.00.

In other news, Director Craig R. Stapleton acquired 140,000 shares of Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share stock in a transaction dated Friday, December 15th. The shares were purchased at an average cost of $8.67 per share, for a total transaction of $1,213,800.00. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 5.07% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of AVDL. Stonepine Capital Management LLC grew its position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 31.7% during the 3rd quarter. Stonepine Capital Management LLC now owns 985,210 shares of the company’s stock worth $10,345,000 after acquiring an additional 237,347 shares during the last quarter. Janney Montgomery Scott LLC bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter worth approximately $2,100,000. Boston Partners bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter worth approximately $1,868,000. Perceptive Advisors LLC grew its position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share by 8.4% during the 3rd quarter. Perceptive Advisors LLC now owns 1,549,005 shares of the company’s stock worth $16,265,000 after acquiring an additional 119,891 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd bought a new position in Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share during the 3rd quarter worth approximately $205,000. Institutional investors and hedge funds own 65.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.thecerbatgem.com/2018/03/12/avadel-pharmaceuticals-plc-american-depositary-shares-each-representing-one-ordinary-share-avdl-short-interest-update.html.

About Avadel Pharmaceuticals plc – American Depositary Shares each representing one Ordinary Share

Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company that seeks to commercialize differentiated pharmaceutical products that are safe, effective and easy to take through formulation development, by utilizing its proprietary drug delivery technology and in-licensing / acquiring new products; ultimately, helping patients adhere to their prescribed medical treatment and see better results.

Receive News & Ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share and related companies with MarketBeat.com's FREE daily email newsletter.